CA3219533A1 - Methods for inhibiting ras - Google Patents
Methods for inhibiting ras Download PDFInfo
- Publication number
- CA3219533A1 CA3219533A1 CA3219533A CA3219533A CA3219533A1 CA 3219533 A1 CA3219533 A1 CA 3219533A1 CA 3219533 A CA3219533 A CA 3219533A CA 3219533 A CA3219533 A CA 3219533A CA 3219533 A1 CA3219533 A1 CA 3219533A1
- Authority
- CA
- Canada
- Prior art keywords
- optionally substituted
- membered
- ras
- alkyl
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163192837P | 2021-05-25 | 2021-05-25 | |
| US63/192,837 | 2021-05-25 | ||
| PCT/US2022/030823 WO2022251292A1 (en) | 2021-05-25 | 2022-05-25 | Methods for inhibiting ras |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3219533A1 true CA3219533A1 (en) | 2022-12-01 |
Family
ID=82115695
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3219533A Pending CA3219533A1 (en) | 2021-05-25 | 2022-05-25 | Methods for inhibiting ras |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240277796A1 (https=) |
| EP (1) | EP4346898A1 (https=) |
| JP (1) | JP2024521774A (https=) |
| KR (1) | KR20240026526A (https=) |
| CN (2) | CN118557730A (https=) |
| AU (1) | AU2022281343A1 (https=) |
| CA (1) | CA3219533A1 (https=) |
| IL (1) | IL308771A (https=) |
| MX (1) | MX2023013912A (https=) |
| TW (1) | TW202313631A (https=) |
| WO (1) | WO2022251292A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2022005359A (es) | 2019-11-04 | 2022-06-02 | Revolution Medicines Inc | Inhibidores de ras. |
| MX2023003060A (es) | 2020-09-15 | 2023-04-05 | Revolution Medicines Inc | Derivados indolicos como inhibidores de ras en el tratamiento del cancer. |
| AU2022268962A1 (en) | 2021-05-05 | 2023-12-14 | Revolution Medicines, Inc. | Ras inhibitors for the treatment of cancer |
| AR127308A1 (es) * | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| CN118922423A (zh) * | 2022-01-10 | 2024-11-08 | 锐新医药公司 | Ras抑制剂 |
| CN119301132A (zh) * | 2022-06-01 | 2025-01-10 | 豪夫迈·罗氏有限公司 | 用于治疗癌症的卤代吲哚大环化合物 |
| CN119522225A (zh) | 2022-09-29 | 2025-02-25 | 广州嘉越医药科技有限公司 | 大环衍生物及其应用 |
| CR20250329A (es) | 2023-02-14 | 2025-09-12 | Hoffmann La Roche | Compuestos tricíclicos para el tratamiento del cáncer |
| EP4687905A1 (en) * | 2023-03-30 | 2026-02-11 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| TW202446387A (zh) * | 2023-04-06 | 2024-12-01 | 瑞士商赫孚孟拉羅股份公司 | 用於治療癌症之三環化合物 |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| WO2025019318A2 (en) * | 2023-07-14 | 2025-01-23 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2025162395A1 (zh) * | 2024-02-01 | 2025-08-07 | 山东先声生物制药有限公司 | 吲哚衍生物作为ras抑制剂及其应用 |
| CN119431325A (zh) * | 2024-10-31 | 2025-02-14 | 诚达药业股份有限公司 | 一种3-（1h-吡唑-1-基）氮杂环丁烷类化合物及其合成方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210116479A (ko) | 2018-12-21 | 2021-09-27 | 레볼루션 메디슨즈, 인크. | 공동 결합에 참여하는 화합물 및 그의 용도 |
| DE102019122206B4 (de) | 2019-08-19 | 2021-07-08 | Webasto SE | Dachmodul zur Bildung eines Fahrzeugdachs mit Umfeldsensor |
| MX2022005359A (es) | 2019-11-04 | 2022-06-02 | Revolution Medicines Inc | Inhibidores de ras. |
| CN120699039A (zh) | 2019-11-04 | 2025-09-26 | 锐新医药公司 | Ras抑制剂 |
| WO2021091956A1 (en) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
| MX2023003060A (es) | 2020-09-15 | 2023-04-05 | Revolution Medicines Inc | Derivados indolicos como inhibidores de ras en el tratamiento del cancer. |
-
2022
- 2022-05-25 MX MX2023013912A patent/MX2023013912A/es unknown
- 2022-05-25 CN CN202410561373.XA patent/CN118557730A/zh active Pending
- 2022-05-25 EP EP22731928.2A patent/EP4346898A1/en active Pending
- 2022-05-25 CA CA3219533A patent/CA3219533A1/en active Pending
- 2022-05-25 JP JP2023572737A patent/JP2024521774A/ja active Pending
- 2022-05-25 KR KR1020237044138A patent/KR20240026526A/ko active Pending
- 2022-05-25 AU AU2022281343A patent/AU2022281343A1/en active Pending
- 2022-05-25 IL IL308771A patent/IL308771A/en unknown
- 2022-05-25 TW TW111119516A patent/TW202313631A/zh unknown
- 2022-05-25 CN CN202280050079.1A patent/CN117715658A/zh active Pending
- 2022-05-25 WO PCT/US2022/030823 patent/WO2022251292A1/en not_active Ceased
-
2023
- 2023-11-22 US US18/518,027 patent/US20240277796A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN117715658A (zh) | 2024-03-15 |
| TW202313631A (zh) | 2023-04-01 |
| JP2024521774A (ja) | 2024-06-04 |
| MX2023013912A (es) | 2024-02-12 |
| US20240277796A1 (en) | 2024-08-22 |
| IL308771A (en) | 2024-01-01 |
| CN118557730A (zh) | 2024-08-30 |
| WO2022251292A1 (en) | 2022-12-01 |
| EP4346898A1 (en) | 2024-04-10 |
| KR20240026526A (ko) | 2024-02-28 |
| AU2022281343A1 (en) | 2023-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3219533A1 (en) | Methods for inhibiting ras | |
| CA3214155A1 (en) | Methods for inhibiting ras | |
| CA2987019C (en) | Pyrido[3,4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof | |
| AU2018278311B2 (en) | IRE1 small molecule inhibitors | |
| JP4771468B2 (ja) | Ｓｒ蛋白質のリン酸化制御方法、および、ｓｒ蛋白質の活性制御剤を有効成分とする抗ウイルス剤 | |
| ES2375284T3 (es) | Sal de un derivado de fenoxipiridina, o cristal de la misma, y procedimiento de producción de la misma. | |
| KR101960624B1 (ko) | Hiv의 치료를 위한 이소퀴놀린 화합물 | |
| JP6134338B2 (ja) | Ｂ型肝炎ウイルス共有結合閉環状ｄｎａ形成の阻害剤およびそれらの使用方法 | |
| CA3039912A1 (en) | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors | |
| WO2022021841A1 (zh) | 一种新型冠状病毒主蛋白酶的抑制剂及其制备方法和用途 | |
| CA2981371A1 (en) | Anti-alphavbeta1 integrin inhibitors and methods of use | |
| US10941121B2 (en) | Human helicase DDX3 inhibitors as therapeutic agents | |
| CN106432213A (zh) | 作为cftr调节剂的杂芳基衍生物 | |
| CA2886240A1 (en) | Modulation of ire1 | |
| US9573899B2 (en) | USP7 inhibitor compounds and methods of use | |
| CA3013433A1 (en) | Sulfonamide derivative and pharmaceutical composition containing same | |
| WO2013036749A1 (en) | Hcv helicase inhibitors and methods of use thereof | |
| JP6859358B2 (ja) | テトラヒドロインダゾール及びその医学的使用 | |
| CN109476669A (zh) | Lim激酶抑制剂 | |
| CA3174266A1 (en) | Grk2 inhibitors and uses thereof | |
| WO2014063167A1 (en) | Thiazole-based inhibitors of scavenger receptor bi | |
| ES2984207T3 (es) | Inhibidores de la cinasa del complejo de activación transcripcional de Notch ("NACK") y métodos para el uso de los mismos | |
| US20240391880A1 (en) | KCa3.1 INHIBITORS FOR PODOCYTE PROTECTION | |
| WO2023201014A1 (en) | Benzothiazole-phenylsulfonyl-piperidine analogs as activators of n-acylphosphatidylethanolamine hydrolyzing phospholipase d | |
| CN114502161B (zh) | 具有心肌细胞增殖活性的杂环衍生物在治疗心脏病中的用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| P22 | Classification modified |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED Effective date: 20250217 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250513 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250513 |